李书颖,王 永

白癜风是一种导致皮肤色素斑块状脱失的自身免疫性皮肤病。目前的传统治疗包括口服或外用皮质类固醇、钙调磷酸酶抑制剂、光疗和辅助治疗等。这些治疗疗效有限，尚不能满足白癜风患者的治疗需求。在白癜风的新型治疗中，JAK抑制剂包括托法替尼、鲁索替尼和巴瑞替尼等。本文结合国内外相关研究对常用JAK抑制剂临床疗效以及相关研究进展进行综述，以期为白癜风的治疗提供参考。

白癜风；JAK抑制剂；托法替尼；鲁索替尼

[1] ZHANG Y, CAI Y, SHI M, et al. The Prevalence of Vitiligo: A Meta-Analysis [J]. PLoS One, 2016, 11(9): e0163806. [2] EZZEDINE K, ELEFTHERIADOU V, WHITTON M, et al. Vitiligo [J]. Lancet, 2015, 386(9988): 74-84. [3] IWANOWSKI T, SZLĄZAK P, ZABŁOTNA M, et al. Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Polish [J]. Postepy Dermatol Alergol, 2021, 38(4): 636-43. [4] KUBELIS-LóPEZ D E, ZAPATA-SALAZAR N A, SAID-FERNáNDEZ S L, et al. Updates and new medical treatments for vitiligo (Review) [J]. Exp Ther Med, 2021, 22(2): 797. [5] MIGAYRON L, BONIFACE K, SENESCHAL J. Vitiligo, From Physiopathology to Emerging Treatments: A Review [J]. Dermatol Ther (Heidelb), 2020, 10(6): 1185-98. [6] WAŃKOWICZ-KALIŃSKA A, VAN DEN WIJNGAARD R M, TIGGES B J, et al. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo [J]. Lab Invest, 2003, 83(5): 683-95. [7] STRASSNER J P, RASHIGHI M, AHMED REFAT M, et al. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity [J]. J Am Acad Dermatol, 2017, 76(5): 847-55.e5. [8] PALERMO B, CAMPANELLI R, GARBELLI S, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo [J]. J Invest Dermatol, 2001, 117(2): 326-32. [9] YANG L, WEI Y, SUN Y, et al. Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo [J]. Acta Derm Venereol, 2015, 95(6): 664-70. [10] HARRIS J E, HARRIS T H, WENINGER W, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin [J]. J Invest Dermatol, 2012, 132(7): 1869-76. [11] FRISOLI M L, ESSIEN K, HARRIS J E. Vitiligo: Mechanisms of Pathogenesis and Treatment [J]. Annual Review of Immunology, 2020, 38(Volume 38, 2020): 621-48. [12] PLATANIAS L C. Mechanisms of type-I- and type-II-interferon-mediated signalling [J]. Nat Rev Immunol, 2005, 5(5): 375-86. [13] RASHIGHI M, AGARWAL P, RICHMOND J M, et al. CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo [J]. Science Translational Medicine, 2014, 6(223): 223ra23-ra23. [14] RICHMOND J M, MASTERJOHN E, CHU R, et al. CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice [J]. J Invest Dermatol, 2017, 137(4): 982-5. [15] RICHMOND J M, BANGARI D S, ESSIEN K I, et al. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease [J]. J Invest Dermatol, 2017, 137(2): 350-8. [16] O'SHEA J J, SCHWARTZ D M, VILLARINO A V, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention [J]. Annu Rev Med, 2015, 66: 311-28. [17] BANERJEE S, BIEHL A, GADINA M, et al. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects [J]. Drugs, 2017, 77(5): 521-46. [18] RAWLINGS J S, ROSLER K M, HARRISON D A. The JAK/STAT signaling pathway [J]. Journal of Cell Science, 2004, 117(8): 1281-3. [19] MCLORNAN D P, POPE J E, GOTLIB J, et al. Current and future status of JAK inhibitors [J]. Lancet, 2021, 398(10302): 803-16. [20] MEASE P, HALL S, FITZGERALD O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis [J]. N Engl J Med, 2017, 377(16): 1537-50. [21] IBRAHIM O, BAYART C B, HOGAN S, et al. Treatment of Alopecia Areata With Tofacitinib [J]. JAMA Dermatol, 2017, 153(6): 600-2. [22] CRAIGLOW B G, KING B A. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy [J]. JAMA Dermatol, 2015, 151(10): 1110-2. [23] VU M, HEYES C, ROBERTSON S J, et al. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo [J]. Clinical and Experimental Dermatology, 2017, 42(8): 942-4. [24] LIU L Y, STRASSNER J P, REFAT M A, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure [J]. J Am Acad Dermatol, 2017, 77(4): 675-82.e1. [25] GIANFALDONI S, TCHERNEV G, WOLLINA U, et al. Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo [J]. Open Access Maced J Med Sci, 2018, 6(1): 46-8. [26] MCKESEY J, PANDYA A G. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo [J]. J Am Acad Dermatol, 2019, 81(2): 646-8. [27] MOBASHER P, GUERRA R, LI S J, et al. Open‐label pilot study of tofacitinib 2% for the treatment of refractory vitiligo [J]. British Journal of Dermatology, 2020, 182(4): 1047-9. [28] DEISSEROTH A, KAMINSKAS E, GRILLO J, et al. U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis [J]. Clinical Cancer Research, 2012, 18(12): 3212-7. [29] SHEIKH A, RAFIQUE W, OWAIS R, et al. FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology [J]. Ann Med Surg (Lond), 2022, 81: 104499. [30] HARRIS J E, RASHIGHI M, NGUYEN N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA) [J]. J Am Acad Dermatol, 2016, 74(2): 370-1. [31] PERSAUD I, DIAMOND S, PAN R, et al. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs [J]. Int J Pharm, 2020, 590: 119889. [32] BRUMFIEL C M, PATEL M H, SEVERSON K J, et al. Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study [J]. J Invest Dermatol, 2022, 142(8): 2109-16.e4. [33] ROTHSTEIN B, JOSHIPURA D, SARAIYA A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib [J]. J Am Acad Dermatol, 2017, 76(6): 1054-60.e1. [34] HAMZAVI I, ROSMARIN D, HARRIS J E, et al. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial [J]. J Am Acad Dermatol, 2022, 86(6): 1398-401. [35] ROSMARIN D, PASSERON T, PANDYA A G, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo [J]. N Engl J Med, 2022, 387(16): 1445-55. [36] MUMFORD B P, GIBSON A, CHONG A H. Repigmentation of vitiligo with oral baricitinib [J]. Australas J Dermatol, 2020, 61(4): 374-6. [37] DONG J, HUANG X, MA L P, et al. Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro [J]. Dose Response, 2022, 20(2): 15593258221105370. [38] LI X, SUN Y, DU J, et al. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy [J]. Clin Cosmet Investig Dermatol, 2023, 16: 635-8. [39] BLAIR H A. Ritlecitinib: First Approval [J]. Drugs, 2023, 83(14): 1315-21. [40] XU H, JESSON M I, SENEVIRATNE U I, et al. PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor [J]. ACS Chem Biol, 2019, 14(6): 1235-42. [41] RICHMOND J M, STRASSNER J P, ZAPATA L, JR., et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo [J]. Sci Transl Med, 2018, 10(450). [42] EZZEDINE K, PEEVA E, YAMAGUCHI Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial [J]. J Am Acad Dermatol, 2023, 88(2): 395-403. [43] KING B, GUTTMAN-YASSKY E, PEEVA E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results [J]. J Am Acad Dermatol, 2021, 85(2): 379-87. [44] QI F, LIU F, GAO L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review [J]. Front Immunol, 2021, 12: 790125. [45] DAI Z, SEZIN T, CHANG Y, et al. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata [J]. Front Immunol, 2022, 13: 955038. [46] COFFEY G, BETZ A, DEGUZMAN F, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer [J]. J Pharmacol Exp Ther, 2014, 351(3): 538-48. [47] SAMUEL C, CORNMAN H, KAMBALA A, et al. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring [J]. Dermatol Ther (Heidelb), 2023, 13(3): 729-49.

点击下载PDF